Table 2.

Demographic, clinical, and biochemical characteristics of the control group

Patient no.	Age, y	G	Timea	KD	Cr	eGFR	Alb	TC	LDL-C	Pr	Previous IS treatment	Treatment	Vascular disease
1	46	M	30	MN	0.80	>90	2.2	9.5	6.9	11.1	Corticosteroids 4 months, cyclosporine A 10 months, cyclophosphamide 6 months, mycophenolate mofetil 6 months, and rituximab 3 doses 1 gr	Atorvastatin 80 mg	No
2	35	M	33	FSGS	0.84	>90	1.9	9.4	5.8	12.8	Corticosteroids 6 months, cyclosporine A 12 months, and mycophenolate mofetil 6 months	Atrovastatin 80 mg plus ezetimibe 10 mg	No
3	41	M	38	FSGS	0.90	>90	2	8.5	6.4	12	Corticosteroids 6 months and cyclosporine A 6 months	Atorvastatin 80 mg	No
4	36	F	30	MCD	0.75	>90	2.4	8.1	5.5	8.3	Corticosteroids 6 months, tacrolimus 6 months, and rituximab 2 doses 1 gr	Atorvastatin 80 mg	No
5	19	F	29	FSGS	0.91	>90	2	10.6	5.6	7.2	Corticosteroids 6 months, cyclosporine A 6 months, and rituximab 2 doses 1 gr	Atorvastatin 80 mg	No
6	23	M	36	MCD	1.03	>90	2.3	9.9	6.7	8.3	Corticosteroids 6 months, mycophenolate mofetil 6 months, and rituximab 2 doses 1 gr	Atorvastatin 80 mg	No
7	32	F	27	FSGS	0.85	>90	2.1	10.8	6.8	7.9	Corticosteroids 6 months, tacrolimus 6 months, and mycophenolate mofetil 6 months	Atorvastatin 80 mg	No
8	17	M	21	FSGS	1.12	82	2.3	9.1	6.9	6.7	Corticosteroids plus tacrolimus 6 months and rituximab 2 doses 1 gr	Atrovastatin 80 mg plus ezetimibe 10 mg	No

Alb, serum albumin (g/dL); Cr, serum creatinine; eGFR, estimated glomerular filtration rate (ml/min/1.73 m²); F, female; FSGS, focal and segmental glomerulosclerosis; G, gender; IS, immunosuppressor; KD, kidney disease; LDL-C, low-density lipoprotein cholesterol (mmol/L); M, male; MCD, minimal change disease; MN, membranous nephropathy; Pr, proteinuria (g/day); TC, total cholesterol (mmol/L).

^aMonths from diagnosis of nephrotic syndrome.